Teaming up for CAR-T cell therapy.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

6 citing papers in PubMed.

1. Advances and Hurdles in CAR T Cell Immune Therapy for Solid Tumors.Cancers · 2022
   Review
2. Adverse Renal Effects of Anticancer Immunotherapy: A Review.Cancers · 2022
   Review
3. Allogeneic Stem Cell Transplantation in Multiple Myeloma.Cancers · 2021
   Review
4. Novel immunotherapies in multiple myeloma - chances and challenges.Haematologica · 2021
   Review
5. Choosing the Right Therapy for Patients with Relapsed/Refractory Multiple Myeloma (RRMM) in Consideration of Patient-, Disease- and Treatment-Related Factors.Cancers · 2021
   Review
6. European Myeloma Network perspective on CAR T-Cell therapies for multiple myeloma.Haematologica · 2021
   Article

Corrections and comments

• Comment on
  Chimeric antigen receptor T-cell therapy for multiple myeloma: a consensus statement from The European Myeloma Network.2019

Authors and funding

3 authors.

Funding

No grant is acknowledged in the PubMed record.

Abstract

PubMed holds no abstract for this paper.

Indexed as